These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23573745)

  • 1. [Age-related macular degeneration].
    Kernt M; Wolf A; Kampik A
    MMW Fortschr Med; 2013 Feb; 155(2):43-5; quiz 46-7. PubMed ID: 23573745
    [No Abstract]   [Full Text] [Related]  

  • 2. PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Abdelfattah NS; Zhang H; Boyer DS; Sadda SR
    Retina; 2016 Oct; 36(10):1843-50. PubMed ID: 27135213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macular atrophy development in neovascular age-related macular degeneration.
    Călugăru D; Călugăru M
    Eur J Ophthalmol; 2022 Jan; 32(1):NP307-NP308. PubMed ID: 32755234
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Age-related visual loss].
    Neubauer AS; Kernt M
    MMW Fortschr Med; 2013 Feb; 155(2):36-7. PubMed ID: 23573743
    [No Abstract]   [Full Text] [Related]  

  • 8. [Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab].
    Cervera RE; Castro V; Montero J; Torralba C; Gracia A
    Arch Soc Esp Oftalmol; 2014 Jan; 89(1):42-3. PubMed ID: 24269436
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
    Scott AW; Bressler SB
    Curr Opin Ophthalmol; 2013 May; 24(3):190-6. PubMed ID: 23492430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Xu L; Mrejen S; Jung JJ; Gallego-Pinazo R; Thompson D; Marsiglia M; Freund KB
    Retina; 2015 Feb; 35(2):176-86. PubMed ID: 25387047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J
    JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
    [No Abstract]   [Full Text] [Related]  

  • 13. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.
    Johnson D; Sharma S
    Curr Opin Ophthalmol; 2013 May; 24(3):205-12. PubMed ID: 23518613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
    Hall LB; Zebardast N; Huang JJ; Adelman RA
    J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
    Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB
    Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
    Thorell MR; Nunes RP; Chen GW; Doshi RR; Dugar J; George MK; Kim BT; Lowrance MD; Modi D; Nahas Z; Gregori G; Yehoshua Z; Feuer W; Rosenfeld PJ
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):526-33. PubMed ID: 25423632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
    Chan CK; Jain A; Sadda S; Varshney N
    Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravitreal aflibercept and ranibizumab on retinal vessel diameter measured using fluorescein angiography.
    Min JK; Lee S; Park JH; Woo JM; Yang HS
    Acta Ophthalmol; 2018 Jun; 96(4):e546-e547. PubMed ID: 29068524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.